Hemostatic pad EVARREST®

wound surgery

EVARREST was clinically proven to achieve hemostasis more reliably than TachoSil® Patch in a multi-center, randomized study in aortic reconstruction surgery, achieving hemostasis in 3 minutes in 78.8% of cases vs 46.7% (per protocol). EVARREST demonstrated superior hemostatic efficacy in 4 randomized controlled clinical trials across a spectrum of challenging bleeding situations and surgical procedures. After appropriate application and manual compression for 3 minutes, blood seeps into the EVARREST patch rather than pooling beneath it. Blood activates fibrinogen and thrombin to form a clot. Hemostasis is achieved when the clot integrates with the patch and adheres to the tissue surface. 32%-68% of cases in open procedures experience disruptive bleeding events. Challenging and uncontrollable bleeding during surgery is associated with increased mortality rates. When challenging bleeding strikes, surgeons need superior hemostatic efficacy. The patch’s adhesive strength forms a tight yet flexible physical seal that maintains a barrier to bleeding, conforming to a wide range of surgical sites.